Alexandra Snyder, MD, Chief Medical Officer at Generate Biomedicines Joins Navigating Cancer Board
SEATTLE , WA, UNITED STATES, August 23, 2022 — Navigating Cancer
announced today that Alexandra Snyder, MD, Chief Medical Officer at Generate Biomedicines,
has agreed to join its board of directors. Dr. Snyder is succeeding David M. Rubin, Ph.D. who
served on Navigating Cancer’s Board from 2015 to the present.
“We are pleased to welcome Dr. Snyder to Navigating Cancer’s Board and especially value her
point of view as a recognized leader in oncology and therapeutic development,” said Bill Bunker,
Navigating Cancer’s CEO. “Dr. Snyder brings a deep understanding of the healthcare landscape
as well as extensive practical experience as a medical oncologist and scientist to Navigating
Cancer. Her perspectives will be instrumental as we expand our capabilities for patients,
providers, pharmaceutical manufacturers, and other industry participants.”
Dr. Snyder is a medical oncologist and brings a wealth of insight in Clinical Development with
prior experience at Memorial Sloan Kettering and Merck, where she played a leadership role in
the Global Clinical Development team. Dr. Snyder is the Chief Medical Officer at Generate
Biomedicines, the leader in generative biology focused on creating de novo proteins for
innumerable therapeutic needs, and the intention to revolutionize drug development to solve
the most complex biological challenges.
“I’m delighted to join the Board of Navigating Cancer. As a practicing physician, I really appreciate
the value of high-quality communication between patients and their caregivers. In addition, we
have so much to learn from considering our patients’ experiences during treatment that can
help us develop better drugs. Together my work at Navigating Cancer and Generate are both
different avenues to the same goal: helping patients to live long and well.”
“Due to Dr Snyder’s broad oncology domain expertise, she will be a great addition to Navigating
Cancer’s board and help the company achieve the goal of enabling advances in oncology patient
care,” said David M. Rubin, Ph.D., Managing Director at Merck Global Health Innovation Fund,
LLC.
About Navigating Cancer
Navigating Cancer is a digital health company focused on improving the lives of cancer patients
and those who care for them. Our comprehensive Navigating Care® platform helps providers boost their financial performance, enables more effective remote care management, and delivers a better patient experience while providing valuable insights for oncology innovation. With over 2,500 providers using the Navigating Care platform to care for over 1 million patients, it is the most broadly deployed oncology patient management solution in the US. For more information, please visit http://www.navigatingcancer.com or follow Navigating Cancer on
Twitter @navcancer.
Lena Shaw
Navigating Cancer
lshaw@navigatingcancer.com